Trials / Completed
CompletedNCT01144936
Study of VX-985 in Subjects With Chronic Hepatitis C
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study of VX-985 in Subjects With Genotype 1 Chronic Hepatitis C
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study it to evaluate the safety and tolerability of VX-985 in HCV subjects. This study will also evaluate the antiviral activity and pharmacokinetic profile of VX-985.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VX-985 or matching placebo | low dose |
| DRUG | VX-985 or matching placebo | high dose |
| DRUG | VX-985 or matching placebo | dose TBD |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2010-06-16
- Last updated
- 2011-03-09
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01144936. Inclusion in this directory is not an endorsement.